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The effect of the cytokine interleukin-l/3 on the insulin secretory responsiveness of single /I-cells (HIT-TlS) was investigated. In the short-term, 
IL-lp induced a dosage-dependent stimulation of insulin release. In contrast, in the long-term, IL-I,$ inhibited both basal and secretagogue-stimul- 
ated insulin secretion. We also demonstrate the simultaneous presence of specific high and low affinity binding sites for IL-l/3 on @ells. IL-l/I, 
which has been implicated in the pathogenesis of insulin-dependent diabetes, may therefore mediate its opposing effects on p-cells through a specific 
plasma membrane receptor. 
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1. INTRODUCTION 
Insulin-dependent diabetes is characterised by in- 
flammation of the pancreas, insulitis, the severity of 
which correlates with cumulative destruction of the 
insulin-secreting fl cells. Macrophages are the first im- 
mune effector cells observed in insulitis, probably re- 
sulting in high local concentrations of the cytokine 
IL-lfl, which has been implicated as the main effector 
of the autoimmune destruction of ,& cells [ 1,2]. 
IL-lp has contrasting effects on insulin secretion and 
the onset of diabetes, dependent on both time of ex- 
posure and dosage. In vivo, the administration of high 
concentrations of IL-l,& accelerates, whereas lower 
doses reduce the rate of disease onset in the BB rat [3]. 
In addition, insulin release from the perfused pancreata 
of normal animals is inhibited after repeated injection 
of IL-lfl for 5 days [4]. In the short-term, IL-1 is hypo- 
glycaemic when injected into animals [5,6]. Numerous 
studies have demonstrated the in vitro effects of IL-l@ 
on isolated islets of Langerhans [1,2,7-lo]. In general, 
high concentrations of IL-lfl severely inhibit insulin 
biosynthesis, secretion and glucose metabolism and are 
cytotoxic, as revealed by electron microscopy [9] or 
“Cr leakage from labelled cells [lo]. However, in con- 
trast, lower doses of IL-l,&, over shorter periods of ex- 
posure, stimulate insulin secretion from isolated islets. 
During inflammation of the pancreas or insulitis, the 
characteristic lesion of type I diabetes, immune destruc- 
tion is specific for fi cells. However, to date there has 
been only one report dealing with the effects of IL-lb 
on singlefl cells, in this case the RIN m5F cell line [l I]. 
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Further, the mechanism of action of IL-lfl remains 
obscure, although disruptions in mitochondrial func- 
tion have been implicated [12-l 51, possibly mediated by 
the generation of toxic oxygen-free radicals [ 1,2]. 
In the present study, we have investigated the effects 
of IL-lb on insulin secretion from HIT-T15 cells, a 
clonal cell line of pure fl cells. We demonstrate, for the 
first time, the presence of specific receptors for IL-lfl 
on single, insulin-secreting p cells. This observation de- 
fines a specific pathway for b-cell destruction mediated 
by IL-la and may therefore have implications in the 
search for novel therapeutics for insulin-dependent 
diabetes. 
2. EXPERIMENTAL 
2.1. Materials 
Tissue culture media, sera, antibiotics and plastics were purchased 
from Gibco Laboratories (New York, NY, USA). Recombinant hu- 
man IL-l,# was from Collaborative Research (Bedford, MA, USA) or 
from Glaxo Institute of Molecular Biology, Geneva, Switzerland. 
L2sI-IL-l,6 was from Amersham Corporation (Arlington Hts, IL, 
USA). Rat insulin standards were from Novo Laboratories (Danbury, 
CT, USA). All other reagents were purchased from Sigma Chemical 
Co. (St Louis, MI, USA). 
2.2. Methods 
HIT-T15 cells (generously provided by Dr A.E. Boyd III, Baylor 
College of Medicine, Houston, TX, USA) were routinely cultured in 
RPM1 1640 containing 11 mM glucose and supplemented with foetal 
calf serum and antibiotics as we have described [16]. For studies of in- 
sulin release, cells were passaged 2 days prior to each experiment and 
seeded with 4 x ld cells per well in 24-well multiwell plates. On the 
day of the experiment, culture medium was aspirated and replaced 
with medium supplemented with additions as shown. At timed inter- 
vals, aliquots were removed, centrifuged briefly to sediment any de- 
tached cells and stored at - 20°C prior to assay. Insulin release was 
measured by enzyme-linked immunosorbent assay (ELISA) [17], us- 
ing a Bio-Rad 2550 plate reader and Microplate Manager Macintosh 
software. DNA was measured fluorometrically [18]. In order to com- 
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bine and compare data from several experiments, insulin release rates 
are reported as a percentage of the mean rate of control wells in the 
same well and are given as mean + SE [ 161. Mean absolute values of 
insulin release are reported where appropriate. Each test condition 
was assayed at least in triplicate, with 3 replicate wells per experiment. 
Data were analysed by analysis of variance (ANOVA). 
For specific IL-la binding studies, HIT-T15 cells were cultured as 
described above. Cells were washed with 2 x 0.5 ml PBS, pH 7.4, 
then incubated in 0.5 ml PBS/OS% (w/v) glucose/0.5% (v/v) BSA, 
pH 7.6 (incubation buffer), containing 100000 cpm ‘2sI-IL-1~ (sp. 
act. 774291 dpm/pmol) and increasing amounts of IL-la, in tripli- 
cate wells. The experiment was repeated 4 times. Incorporation of 
IL-la was maximal at 3 h at 22°C (data not shown). Following incu- 
bation, the buffer was aspirated and the cells washed with 4 x 0.5 ml 
of ice-cold incubation buffer. The cells were then solubilised with 
0.5 ml 0.1 M NaOH, and the cell-associated radioactivity determined 
by liquid scintillation counting. Non-specific binding was defined as 
the residual radioactivity bound in the presence of 0.25 pM IL-l@. 
Binding isotherms were analysed by non-linear least-squares curve fit- 
ting using the programme LIGAND [19] to determine the maximal 
number of sites and the equilibrium dissociation constant (&). 
3. RESULTS AND DISCUSSION 
IL-lb induced opposing effects on HIT-T15 insulin 
secretion, dependent on both dosage and time, which 
are largely comparable to previously reported observa- 
tions with isolated islets [1,2,7,8]. Overall, HIT cells 
proved to be more sensitive to the effects of IL-l@ than 
islets, as shown by the lower doses required to trigger 
either the stimulatory or inhibitory responses. This may 
simply be because a monolayer of single p cells (HIT 
cells) presents less of a diffusion barrier to cytokines 
than does an aggregate mixture comprised of both ,B 
and non+3 cells (islets). 
In long-term incubations (48 h; fig.la), IL-l,B in the 
range 0.005-50.0 U/ml, induced a dosage-dependent 
inhibition of insulin release. Maximal inhibition (30% 
of control) was evident at 0.5 U/ml. The inhibitory 
threshold was between 0.01 and 0.05 U/ml IL-l,&. That 
this effect represents a specific inhibition of insulin 
secretion is supported by two additional observations. 
First, HIT-T15 DNA content (768.8 + 23.8 ng/106 cells 
(n = 8)) was not affected by IL-1,B. Therefore, the re- 
duced levels of insulin accumulated in the medium dur- 
ing a 48 h exposure to cytokine are not merely due to a 
reduced number of cells. In addition, the subsequent in- 
sulinotropic response to secretagogues was also shown 
to be impaired after a 48 h preincubation with IL-l/3. 
Here, cells were preincubated in the presence or absence 
of IL-l,B (25 U/ml or - 1 PM) for 48 h, washed, and 
then challenged with the adenylate cyclase activator, 
forskolin (lOpmol/l), or the sulphonylurea, glibenclam- 
ide (20 pug/ml), for a total of 90 min (fig. lb). In control 
incubations, both forskolin and glibenclamide signifi- 
cantly (P~O.001) potentiated insulin release. However, 
following preincubation with IL-lfl, control, forskolin- 
and glibenclamide-stimulated secretory responses were 
all significantly (P<O.Ol) inhibited. IL-l/3 therefore 
also inhibits insulinotropic activity that is potentiated 
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Fig. 1. Long-term (48 h) inhibitory effect of IL-lb on HIT-T15 insulin 
secretion (a) dosage-dependent i hibition (P< 0.001, ANOVA) of in- 
sulin release following a 48 h incubation with IL-la (0.005-50.0 
U/ml). Insulin release was measured by ELISA. Mean absolute con- 
trol insulin release: 8621.7 pU/ml (n = 6). (b) Effect of preincubation 
with IL-la on secretagogue r sponsiveness of HIT-T15 cells. Cells 
were preincubated in the presence or absence of 25 U/ml IL-la for 
48 h, washed, then challenged with forskolin (10 ,uM) or glibenclam- 
ide (20 ,ug/ml) for a total of 90 min. Insulin release was measured by 
ELISA. In controls, forskolin and glibenclamide potentiated insulin 
release (“P< 0.01, ANOVA). However, preincubation with IL-l@ in- 
duced significant inhibition (*P<O.Ol, ANOVA) of control, 
forskolin- and glibenclamide-stimulated insulin release. Mean ab- 
solute values for control insulin release: 45 min, 450.0 /U/ml (n = 3); 
90 min, 1572.9 ,uU/ml (n = 3). 
by either increased P-cell CAMP or through regulation 
of the ATP-dependent potassium channel. 
In contrast to the inhibition of insulinotropic re- 
sponses een in long-term experiments, IL-lp (0.1-50.0 
U/ml) induced an overall 2-fold potentiation of insulin 
release in short-term incubations (45, 90 min; fig.2), 
similar to the potentiated secretory response reported 
previously in islets [7,8]. The question as to how IL-l 
may have opposing effects on ,B cell function, and 
whether these events are mediated by corresponding or 
disparate mechanisms, still remains largely un- 
answered. 
Zawalich and colleagues [20-221 have shown that 
IL-l actuates glucose-dependent, stimulatory or in- 
hibitory effects on fl cell function, either of which may 
be mediated by phosphoinositide (PI)-derived second 
messengers. Thus, prior short-term exposure of islets to 
IL-l potentiated the first-phase insulin secretory re- 
sponse to a subsequent glucose challenge [20]. In con- 
trast, prolonged exposure ultimately resulted in defects 
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Fig.2. Short-term insulinotropic effect of IL-la in HIT-T15 cells. 
Dosage-dependent s imulation (P<O.Ol, ANOVA) of HIT cell in- 
sulin release over 90 min incubation with IL-la (0.1-50.0 U/ml). In- 
sulin release was measured by ELISA. Mean absolute values for con- 
trol insulin release: 45 min, 422.6pU/ml (n = 3); 90 min, 2792.8 
pU/ml (n = 3). 
in both first- and second-phase secretory responses to 
glucose. This potentiatory effect on glucose-stimulated 
insulin secretion was subsequently extended to stimula- 
tion by cholecystokinin, tolbutamide, leucine or glycer- 
aldehyde, and in each case vvas accompanied by PI 
hydrolysis [21,22]. However, prolonged exposure to 
IL-1 appears to desensitize the cell to glucose, an event 
which is accompanied by an impairment in PI hydro- 
lysis [22]. One consequence of this impaired PI hydro- 
lysis would be a reduced ,&cell diacylglycerol (DAG) 
content and, consequently reduced activity of protein 
kinase C. The observation that 1 -monooleoyglycerol (a 
diacylglycerol kinase inhibitor which increases DAG 
content, thereby activating protein kinase C), signifi- 
cantly restored insulin release inhibited by IL-l is con- 
sistent with this proposition [22]. A second messenger 
role for Ca2’ in insulin secretion is now firmly estab- 
lished. IL-l is known to increase intracellular Ca2+ in 
human neutrophils, and may also mobilise membrane- 
associated Ca2+ [B]. ,d Cell calcium homeostasis is clear- 
ly an area that may be associated with the short-term 
potentiation of insulin release by IL-l, and deserves 
further study. The impairment of intracellular Ca2+ 
homeostasis in the long-term inhibition of insulin secre- 
tion by IL-l,& is suggested by the observation that an 
18 h exposure to IL-lfi has been shown to inhibit the 
voltage-dependent uptake of Ca2+ in islets [23]. 
In their compelling model of type I diabetes, which 
views IL-lfi as the main effector cell associated with ,& 
cell destruction, Nerup and colleagues have alluded to 
the considerable circumstantial evidence implicating 
free radical generation as a major component of cyto- 
kine damage [1,2,7]. Recently, Sumoski et al. furnished 
support in favour of this hypothesis by showing that a 
combination of the free radical scavengers, dimethyl- 
thiourea (DMTU; 1 mM) and citiolone (3 mM), offered 
protection against cytokine lysis of rat islet monolayers 
[24]. However, at best, protection was only 25-30% 
above controls, suggesting that although induction of 
oxygen-free radicals by IL-l,0 is possible, it cannot ac- 
count for all of the damage to ,f3 cells. Further, other 
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Fig.3. IL-lfl binding isotherm for HIT-T15 cells. Binding of IL-l,& to 
HIT cells was specific and saturable. Analysis by non-linear least- 
squares curve fitting revealed binding sites of high and low affinity. 
Data are mean + SE (n = 3) for a single assay, representative of a 
total of 4 experiments. Where SE bars are not present, they are 
smaller than mean experimental values. 
workers have found no effect with DMTU [14]. Like- 
wise, in preliminary studies we have not found any pro- 
tective effects of free radical scavengers, including 
DMTU, on cytokine-induced amage in HIT-T15 cells 
(unpublished observations). This point will only be re- 
solved if oxygen-free radicals can be unequivocally 
demonstrated in single /3 cells. In an attempt o achieve 
this, we are currently applying electron spin resonance 
to HIT-T15 cells in the presence of cytokines. 
In addition to its effects on insulin-secreting ,0 cells, 
IL-l invokes a copious number of endocrine and im- 
munological effects in a myriad of cell types [25]. Fur- 
ther, although the biochemical mechanisms remain am- 
biguous, it is now known that many of these cells bind 
IL-l in a specific and saturable manner [25]. In other 
words, the capacity to respond to IL-l normally cor- 
relates with the presence of specific plasma membrane 
receptors. Accordingly, we have looked for IL-l recep- 
tors on HIT-T15 cells. Fig.3 shows that HIT-T15 cells 
bind IL-lb in a specific and saturable manner. This is 
consistent with the presence of specific plasma mem- 
brane receptors for IL-l in pancreatic p cells. More- 
over, Scatchard analysis (data not shown) of the bind- 
ing data revealed a curvilinear profile. This suggested 
two categories of binding site: a high affinity site (& = 
0.203 f 0.032 (n = 4) nM) with an average of 450 f 122 
sites per cell (n = 4), and a low affinity site (& = 
1.410 f 0.758 (n = 4) nM) with an average of 
1332 + 355 (n = 4) sites per cell. fl cells may therefore 
simultaneously possess both high and low affinity 
receptors for IL-,&, as do many T-cell lines and other 
normal cells (which also show similar ranges in Kd 
values and numbers of binding sites) [25]. 
The demonstration of specific receptors for IL-lfl on 
insulin-secreting ,& cells provides a further step towards 
gaining an understanding of how cytokines may explic- 
itly mediate autoimmune destruction during the pro- 
gression of insulitis. Studies aimed at defining (i) the 
regulation of receptor activity and expression, and (ii) 
the second messengers linking receptor activity to the 
biological responses of fl cells, may reveal novel thera- 
99 
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peutic approaches for the treatment of insulin- 
dependent diabetes. 
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